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Abstract
Personalised medicine is challenging core elements of public health 
practice to bring about a paradigm shift. Traditional public health 
activities such as prevention, screening programmes, infectious 
diseases control, financing and planning of health systems will all be 
affected by developments in genomics. There is a need to move away 
from the traditional high-risk versus population approach debate and 
to engage with concepts of population stratification and public health 
genomics. Public health through its activities of surveillance, needs 
assessment, education and policy advocacy has a critical role to play in 
shaping the entry of personalised medicine into health systems.   
Educational aims
•	 To increase awareness about the growing applications of personalised medicine
•	 To appreciate the tensions between public health practice and personalised medicine
•	 To gain an understanding of the manner in which personalised medicine can act as a 
bridge between public health practice and clinical medicine
Introduction
This article explores how personalised 
medicine is challenging core elements of 
public health practice to bring about a 
paradigm shift in the organisation of public 
health services and health care systems. 
Personalised medicine is defined as “an 
emerging practice of medicine that uses an 
individual’s genetic profile to guide decisions 
made in regard to the prevention, diagnosis 
and treatment of disease”.1 Personalised 
medicine is increasingly being used to 
develop custom-tailored individualised 
treatments in the field of oncology and rare 
diseases but also raises hopes of successful 
treatments for common illnesses such as 
cardiovascular disease, diabetes and mental 
disorders. A closely related approach known 
as ‘stratified medicine’ allows decisions to 
be made for sub groups of people depending 
on their genetic risk profile.  Such concepts 
are increasingly being portrayed as the 
future for clinical diagnostic and therapeutic 
medicine.2 However some authors have raised 
ethical issues3 and others have called for 
personalised medicine to move away from 
focussing on targeted treatment for specific 
organ disease and to embrace personalised 
medicine as the holistic treatment of the 
whole person.4,5 The fact that personalised 
medicine and stratified medicine have 
emerged from a focus on the genetic 
material of individuals or sub groups of 
people sharing the same characteristics may 
mistakenly lead one to assume that they 
bear no relevance to public health practice. 
Indeed, the World Health Organisation 
defines public health as “all organised 
measures (whether public or private) to 
prevent disease, promote health and prolong 
life among the population as a whole. Its 
activities aim to provide conditions in which 
people can be healthy and focus on entire 
populations, not on individual patients or 
diseases”. Should public health practice 
be concerned with personalised medicine 
when the scope of activities for public 
health is typically at population level, while 
personalised medicine deals with individuals? 
Some public health pioneers recognised the 
importance of engaging with genetics and 
genomics early on.6 Now, as genomics starts 
to develop a role in common chronic illness 
prevention and treatment, there is a need for 
contributions from public health to become 
more visible.7 Public health practice will not 
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be able to ignore the impact of genomics and 
will need to take into account the concepts 
of population stratification.8
Discussion
Prevention strategies
The debate on the merits of the individual 
high-risk versus population-based 
approaches that characterised preventive 
epidemiology in the second half of the 20th 
century9 has returned in full force, fuelled 
by the advances being made in genetics 
and genomics. It has been proposed that 
the traditional one-size-fits-all approach to 
disease prevention, diagnosis, and treatment 
would be progressively replaced by a more 
individualized and tailor-made approach.10 
Tobacco prevention and control strategies 
provide an interesting example. In no 
other policy area has public health been so 
effective in advocating for an approach that 
is based on strong regulation with measures 
that aim to protect the whole population 
such as taxation and smoke free public 
places. Genetic and neuroscience research 
continues to enhance our understanding of 
addiction and tobacco dependence yet it is 
not known how best to integrate genetic 
information about a complex phenomenon 
like smoking into traditional public health 
population-based approaches. An empirical 
study of stakeholder perspectives found 
that whilst public health approaches remain 
the preferred vehicle for tackling tobacco, 
individualised treatment programmes 
through pharmacogenomics were viewed 
as useful complementary mechanisms to 
support individuals provided that sufficient 
evidence about their effectiveness becomes 
available.11 Unsurprisingly, this study found 
that clinicians were far more open to the 
possibility of using genetic information to 
underpin tobacco prevention and control 
strategies than public health practitioners. 
The way in which knowledge of genetic 
predisposition can affect attitudes to 
prevention is an important factor for public 
health strategies. A study amongst persons 
with Type 2 diabetes found that persons felt 
less responsible for their Type 2 diabetes 
if they received information about their 
genetic predisposition and this information 
also affected attitudes towards prevention.12 
This is relatively unexplored territory and 
has important implications for all persons 
involved in preventive work.
Screening programmes
The genetic basis for public health screening 
programmes is associated with neonatal 
screening. Developments in the genomics 
field are expected to shape the future of 
other screening programmes in areas such as 
cancer and familial hypercholesterolaemia.13 
Cancer screening programmes are an 
important, if somewhat controversial, area 
of public health practice. While population-
based programmes are commonly available 
in many countries for breast, cervical 
and colorectal cancer, the developments 
taking place in the area of genomics could 
allow screening for cancers not previously 
feasible. One such example is ovarian 
cancer, where genetic testing for germline 
mutations associated with higher risk 
is becoming increasingly affordable and 
offers an opportunity to identify higher 
risk women irrespective of known family 
history. Screening for familial breast cancer 
in younger women than those traditionally 
targeted in population based screening 
programmes is another key development. 
There is some evidence to indicate that 
women would be ready to participate in such 
screening programmes.14 Stratified screening 
based on genetic testing is a new approach 
to prevention. Various organisational issues 
would need to be considered before it could 
be introduced. Potential issues that arise 
and would need to be addressed include 
how the offer of screening would be made, 
making sure consent is adequately informed, 
how individuals’ risk would be assessed, the 
age at which risk estimation should occur, 
and the potential use of genetic data for 
other purposes.15  Inter-country differences 
in the genetic profiles could also provide 
an explanation for the varying success 
rates between population based screening 
programmes and would need to be taken into 
account when determining the feasibility of 
establishing stratified screening programmes.
Infectious diseases
The 2009 influenza pandemic exhibited 
a wide spectrum of disease ranging from 
very mild to fatal. Traditional factors 
such as age, comorbidities and being 
immunocompromised failed to explain the 
variations observed. Several lines of evidence 
suggest that different populations have 
disparate degrees of susceptibility and that 
host variation in key genes associated with 
the appropriate immune response could 
play an important role in determining the 
outcome of infection. Genomics applied 
to infectious disease epidemiology, 
prevention and control has important 
implications to identify which populations 
or subgroups may be at highest risk of 
severe infection and target limited amount 
of countermeasures or vaccine to those at 
highest risk.16 
Funding innovative treatment
The use of genotyping to predict outcomes 
and determine the most appropriate 
candidates for treatment has been well 
established in the field of oncology. 
More recently expensive treatment for 
hepatitis C can be carefully planned 
through the use of genotype testing to 
predict outcomes.17 Such applications are 
important in the management of health 
systems that have to deal with competing 
demands on highly limited resources for 
the financing of innovative therapies. 
There is a need for public health tools such 
as health technology assessment to be 
adapted for evaluations on effectiveness 
of personalised medicine early on in the 
development stage.18 Finer targeting 
of treatment for persons who truly 
demonstrate a capacity to benefit may 
radically alter fundamental public health 
concepts such as ‘numbers needed to treat’. 
The call for new methods of financing 
personalised medicines requires strong 
public health stewardship.19 
Conclusion
Balancing the aspirations for personalised 
medicine with public health approaches 
in fiscally constrained health systems 
will not be an easy task but could be 
facilitated through a strong medicine – 
public health partnership.20 The extent to 
which genomics will change public health 
practice depends on the willingness of 
the public health community to embrace 
genomics. The areas of practice within the 
public health impact pyramid developed by 
Frieden21  provide an alternative manner 
of envisioning the positioning of public 
health genomics13 that goes beyond the 
dichotomous high-risk versus population 
approach which is unhelpful to take 
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forward the relationship between public 
health and personalised medicine. The scope 
of public health practice is sufficiently wide 
such that within it, it is possible to identify 
sectors such as screening, where public 
health genomics is already challenging and 
modifying the population-based approach. 
In other sectors such as tobacco control, 
personalised medicine at present does not 
realistically present feasible options to 
overturn established models of prevention 
and control. Public health practitioners 
have an important role to play at multiple 
levels in influencing the development and 
uptake of personalised medicine. The need 
to ensure that public health genomics 
and personalised medicine finds its way 
into public health teaching, research and 
Key points
•	 Personalised medicine is challenging core elements of public health practice.
•	 Prevention, screening and infectious diseases activities may need to take population 
stratification into account.
•	 Public health is not antagonistic to personalised medicine but has an important role 
to play in shaping the entry of personalised medicine into health systems.
•	 Personalised medicine may become the bridge between the specialities of medicine 
and public health.
practice cannot be underestimated if 
public health is to evolve to meet the 
needs and challenges facing society in 
the 21st century. Equally public health 
through its activities of surveillance, needs 
assessment, education and policy advocacy 
has a critical role to play in shaping the 
entry of personalised medicine into health 
systems such that the basic values of equity, 
utility and efficiency, underpinning welfare-
based health systems, prevail.   Indeed 
it is possible that the introduction of 
personalised medicine into health systems 
may become the bridge across the often 
separate worlds of medicine and public 
health.
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